What this pack is
HYTRIN is the brand name in this record; terazosin hydrochloride capsules is the generic name. Read both together with the dosage form (oral capsule).
PACK CHECK · MARKET FIRST
HYTRINGeneric nameterazosin hydrochloride capsules
How this medicine works
The label explains that terazosin relaxes smooth muscle in the prostate and bladder outlet, helping related urinary symptoms; its vascular effect can also lower blood pressure. It does not shrink the prostate or treat prostate cancer, and similar symptoms still need professional evaluation.
Read source: United States ↗Current regulatory record · reviewed 2026-09-02More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- HYTRIN
- Source-scoped market brand names
- HYTRIN · United StatesSource-scoped evidence ↗NDA 019057 (tablets) and NDA 020347 (capsules); historical 1, 2, 5 and 10 mg products, now discontinued.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- terazosin hydrochloride capsules
- Dosage-form class
- Historical HYTRIN included immediate-release oral tablets and capsules. The exact package comparators currently shown are generic terazosin hydrochloride capsules. TEZRULY is a 1 mg/mL oral solution with a different form, concentration, application and measuring method; a shared ingredient does not permit self-conversion or substitution.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. generic DailyMed label (updated 8 Aug 2026)
Terazosin 1 mg per capsule; 100-capsule bottle; current generic comparator
- Product code
- NDC 24689-001-01
- Form and route
- Generic terazosin hydrochloride oral capsule (not an original-brand HYTRIN pack) · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- terazosin (as hydrochloride)
- 1 mglabelled amount per capsule; not an individual's capsule count, starting amount, restart plan or alpha-blocker conversion
- Package
- 100 capsules per bottle
United States label · Current U.S. generic DailyMed label (updated 8 Aug 2026)
Terazosin 2 mg per capsule; 100-capsule bottle; current generic comparator
- Product code
- NDC 24689-002-01
- Form and route
- Generic terazosin hydrochloride oral capsule (not an original-brand HYTRIN pack) · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- terazosin (as hydrochloride)
- 2 mglabelled amount per capsule; not an individual's capsule count, starting amount, restart plan or alpha-blocker conversion
- Package
- 100 capsules per bottle
United States label · Current U.S. generic DailyMed label (updated 8 Aug 2026)
Terazosin 5 mg per capsule; 100-capsule bottle; current generic comparator
- Product code
- NDC 24689-003-01
- Form and route
- Generic terazosin hydrochloride oral capsule (not an original-brand HYTRIN pack) · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- terazosin (as hydrochloride)
- 5 mglabelled amount per capsule; not an individual's capsule count, starting amount, restart plan or alpha-blocker conversion
- Package
- 100 capsules per bottle
United States label · Current U.S. generic DailyMed label (updated 8 Aug 2026)
Terazosin 10 mg per capsule; 100-capsule bottle; current generic comparator
- Product code
- NDC 24689-004-01
- Form and route
- Generic terazosin hydrochloride oral capsule (not an original-brand HYTRIN pack) · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-02; actual marketing, stock and availability are not established.
- terazosin (as hydrochloride)
- 10 mglabelled amount per capsule; not an individual's capsule count, starting amount, restart plan or alpha-blocker conversion
- Package
- 100 capsules per bottle
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
Enlarged terazosin label: separate per-capsule mg, bottle count and first/restart risk
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The 1, 2, 5 and 10 mg figures are labelled terazosin per capsule; 100 Capsules is the bottle count. The label prominently warns about marked blood-pressure lowering, orthostatic hypotension and syncope when starting, increasing a strength or restarting after several days; the site does not turn dosing text into an individual plan.
- Older adults, people with falls, those rising at night or using another blood-pressure medicine should have the full list, recent interruption and symptoms reviewed. Do not self-restart, increase, separate or stop a pack.
- The label reports hypotension with PDE-5 inhibitors. If CIALIS, VIAGRA or a similar medicine is on the same list, do not self-design spacing or dose reductions.
- Before cataract surgery, tell the eye team about current or previous terazosin/other alpha-1 blocker use; the label says self-stopping has not shown benefit.
- Syncope or a fall with injury needs timely medical assessment. A painful erection lasting for hours is a rare but urgent labelled warning requiring immediate emergency care.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-02
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 3
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. generic terazosin hydrochloride capsule label, patient information and safety warnings ↗Current regulatory record · reviewed 2026-09-02
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-02DailyMed (NLM): enlargeable electronic label PDF for terazosin hydrochloride capsules ↗Current regulatory record · reviewed 2026-09-02
- U.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-02DailyMed (NLM): four exact current generic Apnar terazosin hydrochloride package panels (ANDA 074823) ↗Current regulatory record · reviewed 2026-09-02
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about HYTRIN (terazosin hydrochloride capsules). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
HYTRIN is the brand in this record and terazosin hydrochloride capsules is the active-ingredient name. Check both with the dosage form (Historical HYTRIN included immediate-release oral tablets and capsules. The exact package comparators currently shown are generic terazosin hydrochloride capsules. TEZRULY is a 1 mg/mL oral solution with a different form, concentration, application and measuring method; a shared ingredient does not permit self-conversion or substitution.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. generic terazosin hydrochloride capsule label, patient information and safety warnings ↗Current regulatory record · reviewed 2026-09-02
- DailyMed (NLM): enlargeable electronic label PDF for terazosin hydrochloride capsules ↗Current regulatory record · reviewed 2026-09-02
- DailyMed (NLM): four exact current generic Apnar terazosin hydrochloride package panels (ANDA 074823) ↗Current regulatory record · reviewed 2026-09-02
HOW IT WORKS · NOT A TREATMENT PLAN
How terazosin works: alpha-1 adrenergic blockade affects lower-urinary-tract smooth muscle and vascular resistance
- HYTRIN, FLOMAX, RAPAFLO, UROXATRAL, CARDURA and MINIPRESS are not one medicine. Related alpha blockade creates no milligram conversion, alternation, combination or substitution rule.
- Historical HYTRIN tablets, historical HYTRIN capsules, current generic capsules and TEZRULY oral solution are different exact products. Form and figures must be checked with the pack, prescription and current target-market label.
- Mechanism does not replace blood pressure, the complete medicine list, fall history and individual assessment, or identify a medicine from nocturia or urinary difficulty alone.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: HYTRIN-specific approval history in the 2025 TEZRULY clinical review (NDA 019057/020347) ↗reviewed 2026-09-02
- DailyMed (NLM): current U.S. generic terazosin hydrochloride capsule label, patient information and safety warnings ↗Current regulatory record · reviewed 2026-09-02
- DailyMed (NLM): enlargeable electronic label PDF for terazosin hydrochloride capsules ↗Current regulatory record · reviewed 2026-09-02
- DailyMed (NLM): four exact current generic Apnar terazosin hydrochloride package panels (ANDA 074823) ↗Current regulatory record · reviewed 2026-09-02
SOURCE-TRACEABLE ARCHIVE
HYTRINterazosin hydrochloride capsules
This page includes an exact current U.S. public-label package panel for HYTRIN, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
FDA first approved HYTRIN tablets
NDA 019057; historical 1, 2, 5 and 10 mg tablets.
FDA: HYTRIN-specific approval history in the 2025 TEZRULY clinical review (NDA 019057/020347) ↗BPH-related approval added
Historical milestone recorded in the 2025 FDA review.
FDA: HYTRIN-specific approval history in the 2025 TEZRULY clinical review (NDA 019057/020347) ↗FDA approved HYTRIN capsules
NDA 020347; historical 1, 2, 5 and 10 mg capsules.
FDA: HYTRIN-specific approval history in the 2025 TEZRULY clinical review (NDA 019057/020347) ↗
MARKET SCOPE
Market-record boundary
U.S. HYTRIN
Historical originator/RLD, discontinuedFDA review states discontinuation was not for safety or effectiveness; this does not indicate current stock.
U.S. generic comparator
Current public label and package panelsANDA 074823; 1, 2, 5 and 10 mg in 100-capsule bottles; not original-brand HYTRIN.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Are the pictured bottles original-brand HYTRIN?
No. They are explicitly marked as current generic comparators under ANDA 074823. FDA review supports HYTRIN's historical identity, but the site does not pass current generic images off as historical originator appearance.
Can I restart the old strength after missing several days?
The site cannot provide an individual restart plan. The label specifically warns that restarting after several days can again cause marked blood-pressure lowering and syncope; contact the prescriber or pharmacist with the exact pack, interruption duration, blood pressure, falls/dizziness and full medicine list.
Can it be switched to FLOMAX, RAPAFLO or CARDURA?
That conclusion cannot be made from a similar use or alpha-blocking mechanism. Ingredients, forms, strengths, applications and labels differ, so do not self-convert, alternate or combine them milligram for milligram.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.